OncoMed's demcizumab fails Phase II pancreatic cancer trial

By Jaime De Leon | Apr 10, 2017 | 5:48 PM GMT

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) sank $3.21 (37%) to $5.55 on Monday after reporting that demcizumab (OMP-21M18) missed the primary endpoint in the Phase II YOSEMITE trial to treat metastatic pancreatic cancer in

Read the full 322 word article

How to gain access

Continue reading with a
two-week free trial.